NeurogesX prices IPO below range, raises $44M
NeurogesX, a San Carlos, Calif., biotech focused on pain medication, priced its IPO yesterday at $11 per share, below its expected range of $13 to $15. The company raised approximately $44 million, down from an expected $69 million.
The company’s lead drug candidate, NGX-4010, is a transdermal skin patch designed to deliver low doses of synthetic capsaicin — a version of the active ingredient that makes chili peppers spicy — directly to the site of chronic… Continue Reading
NeurogesX, chronic pain treatment co., files for $69M IPO
Updated
NeurogesX, a San Carlos drug company developing treatments for chronic pain, has filed for an initial public offering to raise $69 million.
NeurogesX has raised about $95 million from venture firms, including Alta Partners, Arch Venture Partners, Montreux Equity Partners and Walden International.